Serpin Pharma is pioneering a new class of therapeutics aimed at enhancing the body's natural immune response through its lead product, SP16. This innovative therapeutic is derived from a natural SERPIN protein, specifically a modified fragment of Alpha-1 Antitrypsin (AAT), which has been engineered to selectively target the LRP1 receptor. By binding to this receptor, SP16 effectively restores inflammatory balance by removing harmful inflammatory triggers from the cell surface, activating key survival pathways, and deactivating pro-inflammatory pathways. This mechanism not only mitigates excessive inflammation but also promotes cell and tissue repair, positioning SP16 as a promising solution for a variety of inflammatory diseases.

The therapeutic potential of SP16 extends to multiple indications, including acute myocardial infarction, acute lung injury, and various inflammatory skin diseases. Preclinical studies have demonstrated its efficacy in reducing inflammation and improving outcomes in conditions characterized by excessive immune responses. Notably, SP16 has shown significant promise in clinical trials, with no known adverse effects reported thus far. Serpin Pharma's robust patent portfolio, which includes 13 approved patents, underscores the innovative nature of their technology and its potential to address unmet medical needs in the growing global anti-inflammatory therapeutics market.

United States

Serpin Pharma is a biotech company that develops targeted therapeutics to enhance the body's natural immune response, reducing inflammation and restoring immune balance.

Serpin Pharma

Company Details